Mechelen, Belgium; 29 June 2010 - Galapagos NV (Euronext: GLPG) issued a correction regarding a transparency notification received on 28 June 2010, pursuant to the Belgian transparency legislation (Belgian Act of 2 May 2007) concerning major holdings in Belgian listed companies.
The notification received on 28 June 2010 was submitted on behalf of Mr. A. Strating, TWE Beheer, TWE Investment, and Gestion Deelnemingen IV (not Gestion Deelnemingen V as erroneously stated in the press release on 28 June 2010) who declared a combined holding of 1,252,550 shares (5.2%) of Galapagos. This shareholding is separate from the 1,184,602 shares (5.0%) held by Gestion Deelnemingen V.
Major shareholders of Galapagos NV as of 29 June 2010:
| Shareholder | Number of shares | Percentage of total |
| Delta Lloyd Levensverzekering NV | 2,857,750 | 12.0% |
| Abingworth Management Limited | 1,576,327 | 6.6% |
| Mr. A. Strating, TWE Beheer BV, TWE Investment BV, Gestion Deelnemingen IV BV | 1,252,550 | 5.2% |
| Crucell Holland BV | 1,236,097 | 5.2% |
| Gestion Deelnemingen V BV | 1,184,602 | 5.0% |
| Johnson & Johnson | 1,113,964 | 4.7% |
| GlaxoSmithKline | 513,281 | 2.1% |
| Insiders | 354,426 | 1.5% |
| Other shareholders | 13,801,041 | 57.7% |
| TOTAL | 23,890,038 | 100% |
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with four clinical and over 50 small molecule discovery/pre-clinical programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, Merck & Co. and Roche, Galapagos is eligible to receive up to €3 billion in downstream milestones, plus royalties. Together with its BioFocus and Argenta service operations, Galapagos has over 670 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More info at: www.glpg.com
CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com
This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.